No matches
Type 2 Inflammation

2025 ADVENT Forum | Potential for Disease Modification in the Airway

Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.
Klaus Rabe
Leonard Bacharier
Eugenio De Corso
MD, PhD, FERS
Klaus Rabe +5 more

Learning objectives

  • Identify and describe current and emerging therapeutic strategies that demonstrate potential for disease modification in various airway conditions.
  • Recognize the current challenges and future opportunities in translating research on disease modification into routine clinical practice
Tags
disease modificationupper airwaytype 2 inflammation
MAT-GLB-2503987 - 1.0 - 07/2025

About these experts

Pulmonology
MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

Allergy/Immunology
MD

Leonard Bacharier

Janie Robinson and John Moore Lee Chair of Pediatrics and Director of Center for Pediatric Asthma Research | Vanderbilt University, Tennessee, United States

Rhinology
MD, PhD

Eugenio De Corso

Adjunct Professor of Otorhinolaryngology | Catholic University of the Sacred Heart, Milan, Italy

Rhinology
MD

Stella Lee

Chief of Rhinology at Brigham and Women’s Hospital | Harvard Medical School, Boston, United States

Pulmonology
MD, PhD

Celeste Porsbjerg

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

Rhinology
MD, PhD

Martin Wagenmann

Head of Rhinology, Allergy, and Endoscopic Skull Base Surgery and Head of the Research Laboratory in the ENT Department | University Hospital of Düsseldorf, Germany

Related resources

ERS 2023 | Adult Asthma Symposium: Mini Debate
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Mini Debate

ERS 2023 | Adult Asthma Symposium: Panel Discussion
Pulmonology
expert video

ERS 2023 | Adult Asthma Symposium: Panel Discussion

ERS 2023 | Advancing Asthma Management Beyond Control
Pulmonology
expert video

ERS 2023 | Advancing Asthma Management Beyond Control

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Assessing Disease Activity to Better Define On-Treatment Clinical Remission in Pediatric Severe Asthma

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Burden of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​
Pulmonology
expert video

ERS 2023 | Evolving Patient Care: From Symptom Control to On-Treatment ​Clinical Remission​

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?
Pulmonology
expert video

ERS 2023 | How Achievable Is Clinical Remission on Biologic Therapy?

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?
Pulmonology
expert video

ERS 2023 | On-Therapy Remission in Pediatric Asthma: Where Are We Today?

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion
Pulmonology
expert video

ERS 2023 | Pediatric Asthma Symposium: Patient Case Discussion

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma
Pulmonology
expert video

ERS 2023 | Progression of Underlying Disease in Pediatric Severe Asthma

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management
Pulmonology
expert video

ERS 2023 | Type 2 Biomarkers as Predictive and Prognostic Tools to Guide Management

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective
Rhinology
expert video

IRS-ISIAN 2024 | Remission in CRSwNP: A Real-World Perspective

Multidisciplinary Partnership for Type 2 Inflammatory Diseases
Type 2 Inflammation
expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future
Rhinology
expert video

ERS-ISIAN 2023 | Implementation of Guidelines into Daily Practice: Past, Present, and Future

Type 2 Inflammation Underpins Pediatric Severe Asthma
Pulmonology
Infographic

Type 2 Inflammation Underpins Pediatric Severe Asthma

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP
Rhinology
expert video

IFOS 2023 | Type 2 Inflammation and Clinically Relevant Improvements in CRSwNP

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP
Rhinology
expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes
Rhinology
expert video

Expert Discussion: Partnering With Patients to Improve CRSwNP Outcomes

Clinical Management of CRSwNP: Maximizing Symptom Improvement
Rhinology
expert video

Clinical Management of CRSwNP: Maximizing Symptom Improvement

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP
Rhinology
expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age
Pulmonology
interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD
Type 2 Inflammation
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP
Rhinology
expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation
Rhinology
expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

Importance of Lung Function Assessment in Pediatric Asthma Patients
Pulmonology
videoanimation

Importance of Lung Function Assessment in Pediatric Asthma Patients

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?
Pulmonology
Podcast

ADVENT On Air | What Is the Future Outlook for Remission in Pediatric Severe Asthma?

ADVENT On Air | Loss of Smell in CRSwNP Patients
Rhinology
Podcast

ADVENT On Air | Loss of Smell in CRSwNP Patients

ADVENT On Air | Remission in CRSwNP
Rhinology
Podcast

ADVENT On Air | Remission in CRSwNP

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care
Pulmonology
videoanimation

Lung Function Assessment Is a Fundamental Component of Optimal Asthma Care

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?
Pulmonology
videoanimation

How Can Poor Lung Function Impact Asthma Burden in Pediatric Patients?

Role of Type 2 Inflammation Across Different Chronic Diseases
Type 2 Inflammation
expert video

Role of Type 2 Inflammation Across Different Chronic Diseases

Trajectories of Type 2 Inflammation in Pediatric Patients
Type 2 Inflammation
expert video

Trajectories of Type 2 Inflammation in Pediatric Patients

Evolving Topics in Type 2 Inflammation
Type 2 Inflammation
expert video

Evolving Topics in Type 2 Inflammation

Connecting the Dots from Type 2 Inflammation to Patient Perspectives
Type 2 Inflammation
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission
Pulmonology
expert video

EAACI 2024 Moving Beyond Control To On-Treatment Clinical Remission

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma
Pulmonology
expert video

EAACI 2024 Emerging Definitions of Clinical Remission and Achieving Clinical Remission With Biologics for Patients With Asthma

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care
Pulmonology
expert video

EAACI 2024 Evolving Perspectives in CRSwNP Patient Care

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma
Pulmonology
Podcast

ADVENT On Air | The Road Ahead: Achieving Remission for ​Patients With Asthma

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
Rhinology
expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
Rhinology
expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

Dr. Giorgio Canonica Regarding Multidisciplinary Approach
Rhinology
expert video

Dr. Giorgio Canonica Regarding Multidisciplinary Approach

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?
Rhinology
expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

Eosinophils as a Biomarker for Type 2 Asthma
Pulmonology
expert video

Eosinophils as a Biomarker for Type 2 Asthma

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13
Pulmonology
expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

COPD and Asthma: What's the Difference and Is There a Link?
Pulmonology
interactivity

COPD and Asthma: What's the Difference and Is There a Link?

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology
Pulmonology
expert video

ERS 2023 | The Impact of Type 2 Inflammation on COPD: Examining Its Role in Disease Pathophysiology

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD
Pulmonology
expert video

GOLD 2023 | Beyond a One Size Fits All Approach: Recognizing the Heterogeneity of COPD

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features
Pulmonology
expert video

GOLD 2023 | Role of Underlying Inflammation in COPD Pathology and Clinical Features

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region